Mostrar el registro sencillo del ítem
Implication of green tea as a possible therapeutic approach for Parkinson disease
dc.contributor.author | Jurado-Coronel J.C. | |
dc.contributor.author | Ávila-Rodriguez M. | |
dc.contributor.author | Echeverria V. | |
dc.contributor.author | Hidalgo O.A. | |
dc.contributor.author | Gonzalez J. | |
dc.contributor.author | Aliev G. | |
dc.contributor.author | Barreto G.E. | |
dc.date.accessioned | 2020-09-02T22:21:03Z | |
dc.date.available | 2020-09-02T22:21:03Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.2174/1871527315666160202125519 | |
dc.identifier.citation | 15, 3, 292-300 | |
dc.identifier.issn | 18715273 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/4988 | |
dc.description | Green tea is a beverage consumed around the world that is believed to have substantial health benefits such as reducing the risk of cancer, cardiovascular diseases, diabetes and neurodegeneration. This beverage is prepared from the leaves (steamed and dried) of the Camellia sinesis plant and contains strong antioxidant and neuroprotective phenolic compounds from which the most important is (-)-Epigallocatechin-3-gallate. Parkinson’s disease (PD) is the second more common neurodegenerative disorders, after Alzheimer’s disease and is characterized by degeneration of dopaminergic neurons in the pars compact of the substantia nigra of the basal ganglia. It has been shown in pre-clinical and clinical studies that green tea may be able to prevent PD, but its optimal dose or a possible mechanism explaining its health benefit in PD has not been properly established. In this review, we discuss the potential role of green tea’s phenolic compounds and their therapeutic effectin modulating key signaling pathways in the PD brain. © 2016 Bentham Science Publishers. | |
dc.language.iso | en | |
dc.publisher | Bentham Science Publishers | |
dc.subject | (-)-epigallocatechin-3-gallate | |
dc.subject | Antioxidant | |
dc.subject | Green tea | |
dc.subject | Neuroprotection | |
dc.subject | Oxidative stress | |
dc.subject | Parkinson disease | |
dc.subject | 1 methyl 4 phenylpyridinium | |
dc.subject | alpha synuclein | |
dc.subject | amine oxidase (flavin containing) isoenzyme B | |
dc.subject | amyloid beta protein | |
dc.subject | catechin | |
dc.subject | catechol methyltransferase | |
dc.subject | epigallocatechin gallate | |
dc.subject | Fas antigen | |
dc.subject | Fas ligand | |
dc.subject | growth arrest and DNA damage inducible protein 45 | |
dc.subject | heat shock protein 90 | |
dc.subject | hypoxia inducible factor 1alpha | |
dc.subject | immunoglobulin enhancer binding protein | |
dc.subject | inducible nitric oxide synthase | |
dc.subject | interleukin 1beta | |
dc.subject | iron | |
dc.subject | levodopa | |
dc.subject | mitogen activated protein kinase | |
dc.subject | oxidopamine | |
dc.subject | phosphatidylinositol 3 kinase | |
dc.subject | procollagen proline 2 oxoglutarate 4 dioxygenase | |
dc.subject | protein BAD | |
dc.subject | protein kinase C | |
dc.subject | reactive oxygen metabolite | |
dc.subject | reduced nicotinamide adenine dinucleotide dehydrogenase | |
dc.subject | rotenone | |
dc.subject | tumor necrosis factor alpha | |
dc.subject | tumor necrosis factor related apoptosis inducing ligand | |
dc.subject | ubiquitin conjugating enzyme E2 | |
dc.subject | unindexed drug | |
dc.subject | catechin | |
dc.subject | neuroprotective agent | |
dc.subject | tea | |
dc.subject | aging | |
dc.subject | antioxidant activity | |
dc.subject | apoptosis | |
dc.subject | Article | |
dc.subject | bioavailability | |
dc.subject | Camellia sinensis | |
dc.subject | cell viability | |
dc.subject | clinical examination | |
dc.subject | disease course | |
dc.subject | disorders of mitochondrial functions | |
dc.subject | enzyme activity | |
dc.subject | enzyme inhibition | |
dc.subject | human | |
dc.subject | lipid peroxidation | |
dc.subject | metabolism | |
dc.subject | nervous system inflammation | |
dc.subject | neuroprotection | |
dc.subject | neurotoxicity | |
dc.subject | nonhuman | |
dc.subject | nuclear magnetic resonance imaging | |
dc.subject | oxidative stress | |
dc.subject | Parkinson disease | |
dc.subject | protein binding | |
dc.subject | protein expression | |
dc.subject | tea | |
dc.subject | analogs and derivatives | |
dc.subject | animal | |
dc.subject | chemistry | |
dc.subject | Parkinson disease | |
dc.subject | tea | |
dc.subject | Animals | |
dc.subject | Catechin | |
dc.subject | Humans | |
dc.subject | Neuroprotective Agents | |
dc.subject | Parkinson Disease | |
dc.subject | Tea | |
dc.title | Implication of green tea as a possible therapeutic approach for Parkinson disease | |
dc.type | Article |